Featured Posts

Tuesday, January 15, 2019

These findings indicate a potential therapeutic role of 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucosidein Alzheimer's disease therapy.

PMID:  BMC Complement Altern Med. 2016 Aug 26 ;16(1):320. Epub 2016 Aug 26. PMID: 27565551 Abstract Title:  Impact of 2, 3, 5, 4'-tetrahydroxystilbene-2-O-β-D-glucoside on cognitive deficits in animal models of Alzheimer's disease: a systematic review. Abstract:  BACKGROUND: The efficacy of 2, 3, 5, 4'-tetrahydroxystilbene-2-O-β-D-glucoside (TSG) treatment on cognitive decline in individuals with Alzheimer's disease (AD) has not been investigated. Therefore, we systematically reviewed the effect of TSG on cognitive deficits in a rodent model of AD.METHODS: We identified eligible studies published from January 1980 to April 2015 by searching seven electronic databases. We assessed the study quality, evaluated the efficacy of TSG treatment, and performed a stratified meta-analysis and meta-regression analysis to assess the influence of study design on TSG efficacy.RESULTS: Among a total of 381 publications, 18 fulfilled our inclusion criteria. The overall methodological quality of these studies was poor. The meta-analysis revealed a statistically significant benefit of TSG on acquisition memory (standardized mean difference [SMD] = -1.46 (95 % CI: -1.81 to -1.10, P 

read more

from GreenMedInfo http://bit.ly/2sBflMp

No comments:

Post a Comment